th International Conference on 17 Malignancies in HIV/AIDS October 21-22, 2019 NIH Campus Bethesda, Maryland O˜ce of HIV and AIDS Malignancy | National Cancer Institute National Institutes of Health | U.S. Department of Health and Human Services PROGRAM Day 1: October 21 8:00 a.m. – 8:15 a.m. Day 1 Poster Setup Highlighted Posters (1-8) will stay up for the entire meeting. 8:15 a.m. – 8:20 a.m. Welcome and Introduction Robert Yarchoan, M.D. Director Office of HIV and AIDS Malignancy National Cancer Institute, NIH 8:20 a.m. – 8:30 a.m. Opening Remarks Douglas R. Lowy, M.D. Acting Director National Cancer Institute, NIH 8:30 a.m. – 8:35 a.m. Presentation of NCI Director’s Career Achievement Award to Drs. Patrick S. Moore and Yuan Chang 8:35 a.m. – 9:00 a.m. Plenary 1: 25 Years of KSHV Research Patrick S. Moore, M.D., M.P.H. University of Pittsburgh 9:00 a.m. – 10:00 a.m. Session 1: Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) Moderators: Paul M. Lieberman, Ph.D. The Wistar Institute Thomas S. Uldrick, M.D., M.S. National Cancer Institute, NIH 9:00 a.m. – 9:15 a.m. O1. Functional Analysis of Human and Viral Circular RNAs During Kaposi’s Sarcoma Herpesvirus Infection Takanobu Tagawa, Ph.D. National Cancer Institute, NIH 9:15 a.m. – 9:30 a.m. O2. KSHV Manipulates Host Iron Metabolism and Antioxidant Pathways to Promote Tumorigenesis and Resist Ferroptotic Cell Death Ashlee V. Moses, Ph.D. Oregon Health & Science University 9:30 a.m. – 9:45 a.m. O3. Induction of Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein-1 Robert Yarchoan, M.D. National Cancer Institute, NIH 9:45 a.m. – 10:00 a.m. O4. Characterizing Somatic Cellular Mutations in KS Tumors Warren Phipps, M.D., M.P.H. Fred Hutchinson Cancer Research Center 10:00 a.m. – 10:30 a.m. Break and Poster Viewing - 1 - 10:30 a.m. – 12 noon Session 2: Human Papillomavirus and Associated Diseases Moderators: Joel M. Palefsky, M.D., FRCP(C) University of California, San Francisco Mark H. Einstein, M.D., M.S. Rutgers University 10:30 a.m. – 11:00 a.m. P2. Alternative Outcomes of HPV Infection: Immune Control Versus Neoplastic Progression John Doorbar, M.D. University of Cambridge 11:00 a.m. – 11:30 a.m. P3. Molecular Characteristics of Cervical Cancer in HIV+ and HIV- Ugandan Women Daniela S. Gerhard, Ph.D. National Cancer Institute, NIH 11:30 a.m. – 11:45 a.m. O5. HIV Proteins Gp120 and Tat Induce an Epithelial–Mesenchymal Transition in HPV-Immortalized Anal and Cervical Epithelial Cells and Increase Their Migration and Invasion Sharof Tugizov, Ph.D., D.Sc., D.V.M. University of California, San Francisco 11:45 a.m. – 12 noon O6. Screening Tests for Anal High-Grade Squamous Intraepithelial Lesion Detection in U.S. Women Living With HIV Elizabeth Y. Chiao, M.D., M.P.H. Baylor College of Medicine 12 noon – 1:00 p.m. Lunch (on your own) 1:00 p.m. – 2:00 p.m. Day 1 Poster Viewing (Presenters stand by their posters.) 2:00 p.m. – 3:00 p.m. Session 3: HTLV-1 and Other Pathogens Moderators: Ashlee V. Moses, Ph.D. Oregon Health & Science University Erle S. Robertson, Ph.D. University of Pennsylvania 2:00 p.m. – 2:30 p.m. P4. HTLV-1: New Strain Genoveffa Franchini, M.D. National Cancer Institute, NIH 2:30 p.m. – 2:45 p.m. O7. Virus-like Vesicles as a Vaccine Platform for Kaposi’s Sarcoma-Associated Herpesvirus Ting-Ting Wu, Ph.D. University of California, Los Angeles 2:45 p.m. – 3:00 p.m. O8. A CRISPR Screen Reveals Epigenetic Factors That Restrict B-Cell Epstein-Barr Virus Oncoprotein Expression Benjamin E. Gewurz, M.D., Ph.D. Harvard Medical School 3:00 p.m. – 3:30 p.m. Break and Poster Viewing - 2 - 3:30 p.m. – 5:30 p.m. Session 4: Prevention of HPV-Associated Cancers and Pathobiology of Lymphoma Moderators: Elizabeth Y. Chiao, M.D., M.P.H. Baylor College of Medicine Teresa M. Darragh, M.D. University of California, San Francisco 3:30 p.m. – 4:00 p.m. P5. ANCHOR Trial Update Joel M. Palefsky, M.D., FRCP(C) University of California, San Francisco 4:00 p.m. – 4:30 p.m. P6. Recent Trends in Anal Cancer Incidence: Implications for Prevention Using Disease Simulation Modeling Ashish Deshmukh, Ph.D., M.P.H. University of Texas Health Science Center at Houston 4:30 p.m. – 5:00 p.m. P7. Evaluation of Cervical Images for Cancer Screening Using Artificial Intelligence Algorithms Mark Schiffman, M.D., M.P.H. National Cancer Institute, NIH 5:00 p.m. – 5:15 p.m. O9. PD-L1+ B-Regulatory Cells Are Induced by Exposure to Factors That Are Elevated in HIV-1+ Subjects Who Develop AIDS-NHL Laura E. Martinez, Ph.D. University of California, Los Angeles 5:15 p.m. – 5:30 p.m. O10. Potential Alternative Survival Mechanisms in HIV-Associated Diffuse Large B-Cell Lymphoma (DLBCL) of Germinal Center (GCB) Origin Alanna Maguire, Ph.D., M.Sc. Mayo Clinic Arizona 5:30 p.m. End of Day 1 - 3 - Day 2: October 22 8:00 a.m. – 8:30 a.m. Poster Day 2 Setup and Viewing Highlighted Posters (1-8) will stay up for the entire meeting. 8:30 a.m. – 8:45 a.m. Opening Comments Robert Yarchoan, M.D. Office of HIV and AIDS Malignancy National Cancer Institute, NIH Geraldina Dominguez, Ph.D Office of HIV and AIDS Malignancy National Cancer Institute, NIH 8:45 a.m. – 9:45 a.m. Session 5: Cancer Treatment and Outcomes Moderators: Richard F. Little, M.D. National Cancer Institute, NIH Richard F. Ambinder, M.D., Ph.D. Johns Hopkins University School of Medicine 8:45 a.m. – 9:15 a.m. P8. Cancer Outcomes in Patients With an Underlying HIV Infection: Anna E. Coghill, Ph.D., M.P.H. Moffitt Cancer Center 9:15 a.m. – 9:45 a.m. P9. Cancer in People Living with HIV: Treatment Disparities and Opportunities Gita Suneja, M.D., M.S.H.P. University of Utah 9:45 a.m. – 10:45 a.m. Roundtable: Cancer Treatment in the Era of cART Moderator: Richard F. Little, National Cancer Institute Discussants: Richard F. Ambinder, Surbhi Grover, Lynda Dee, Thomas S. Uldrick, Elizabeth Y. Chiao, Jeff Taylor, and Eric A. Engels 10:45 a.m. – 11:15 a.m. Break and Poster Viewing 11:15 a.m. – 12:15 p.m. Session 6: Epidemiology Moderators: Eric A. Engels, M.D., M.P.H. National Cancer Institute, NIH Keith M. Sigel, M.D. Icahn School of Medicine at Mount Sinai 11:15 a.m. – 11:30 a.m. O11. Factors Associated With Treatment Completion and Treatment Response of Chemoradiation in HIV-Infected Patients in Botswana Surbhi Grover, M.D., M.P.H. University of Pennsylvania 11:30 a.m. – 11:45 a.m. O12. Cancer-Attributable Mortality Among People With HIV in the United States During 2001-2015 Marie-Josèphe Horner, Ph.D. National Cancer Institute, NIH - 4 - 11:45 a.m. – 12 noon O13. Kaposi’s Sarcoma Incidence, Burden, and Prevalence Among Persons With HIV in the United States, 2000-2015 Sally Peprah, Ph.D. National Cancer Institute, NIH 12 noon – 12:15 p.m. O14. Cancer Immunotherapy Use and Effectiveness in Real-World Patients Living With HIV Blythe J.S. Adamson, Ph.D, M.P.H. Flatiron Health 12:15 p.m. – 1:15 p.m. Lunch (on your own) 1:15 p.m. – 2:15 p.m. Day 2 Poster Viewing (Presenters stand by their posters.) 2:15 p.m. – 3:00 p.m. Session 7: Primary Effusion Lymphoma (PEL) Moderators: Denise Whitby, Ph.D. Frederick National Laboratory for Cancer Research, NIH Thomas S. Uldrick, M.D., M.S. National Cancer Institute, NIH 2:15 p.m. – 2:45 p.m. P10. Primary Effusion Lymphoma: What Have We Learned From a Rare Disease Ethel Cesarman, M.D., Ph.D. Weill Cornell Medical College 2:45 p.m. – 3:15 p.m. P11. Gene Essentially Landscape and Druggable Genetic Vulnerabilities of Primary Effusion Lymphoma Eva Gottwein, Ph.D. Northwestern University 3:15 p.m. – 3:45 p.m. Break and Poster Viewing 3:45 p.m. – 5:30 p.m. Session 8: International Studies Moderators: Charles Wood, Ph.D. University of Nebraska-Lincoln Erle S. Robertson, Ph.D. University of Pennsylvania Medical School 3:45 p.m. – 4:15 p.m. P12. Discerning Clinical and Biological Heterogeneity in Pediatric Kaposi Sarcoma Nader K. El-Mallawany, M.D. Texas Children’s Hospital/Baylor College of Medicine 4:15 p.m. – 4:30 p.m. O15. Suspected KSHV Inflammatory Cytokine Syndrome (KICS) in Participants With Mild or Moderate AIDS-KS Enrolled in A5264/AMC067 Is Associated With Inferior Survival Scott V. Adams, Ph.D., M.P.H. Fred Hutchinson Cancer Research Center 4:30 p.m. – 4:45 p.m. O16. Treatment of Advanced AIDS-Associated Kaposi’s Sarcoma (AIDS-KS) in Resource-Limited Settings: A Three-Arm, Randomized, Non-Inferiority Trial in Sub- Saharan Africa and Brazil (ACTG A5263/AMC066) Susan E. Krown, M.D. AIDS Malignancy Consortium - 5 - 4:45 p.m. – 5:00 p.m. O17. Poor Immune Cell Infiltration in the Endemic and Epidemic Kaposi’s Sarcoma Microenvironment Salum J. Lidenge, Ph.D. University of Nebraska–Lincoln 5:00 p.m.